RecruitingPhase 3NCT06282575
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Studying Adenocarcinoma of the gallbladder and extrahepatic biliary tract
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jazz Pharmaceuticals
- Intervention
- Zanidatamab(drug)
- Enrollment
- 286 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2030
Study locations (30)
- City of Hope(City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States
- Rocky Mountain Cancer Centers, LLP, Lone Tree, Colorado, United States
- AdventHealth Hematology and Oncology, Orlando, Florida, United States
- Winship Cancer Institute, Atlanta, Georgia, United States
- The University of Kansas Cancer Center - Westwood, Westwood, Kansas, United States
- Norton Cancer Institute - Audubon, Louisville, Kentucky, United States
- Ochsner Clinic Foundation, New Orleans, Louisiana, United States
- Tufts Medical Center, Boston, Massachusetts, United States
- University of Michigan Hospital, Ann Arbor, Michigan, United States
- Henry Ford Health System, Detroit, Michigan, United States
- Minnesota Oncology Hematology, P.A., Maple Grove, Minnesota, United States
- Atlantic Health System/Morristown Medical Center, Morristown, New Jersey, United States
- Laura and Isaac Perlmutter Cancer Center at NYU Langone - Ambulatory Care Center, New York, New York, United States
- Memorial Sloan Kettering Cancer Centers, New York, New York, United States
- Oregon Health and Science University, Portland, Oregon, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06282575 on ClinicalTrials.govOther trials for Adenocarcinoma of the gallbladder and extrahepatic biliary tract
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07265674A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract CancerJ-Pharma Co., Ltd.
- RECRUITINGNCT07007832Bile Omics for Diagnosing Indeterminate Biliary StricturesShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- ACTIVE NOT RECRUITINGPHASE1NCT03257761Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder CancerUniversity of Southern California
See all trials for Adenocarcinoma of the gallbladder and extrahepatic biliary tract →